|
|
|
|
 |
Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference |
| Companies mentioned in this article: |
|
Arena Pharmaceuticals |
|
| 6/6/2008 @ 2:23 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced today that the company is scheduled to present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time) at the New York Palace Hotel in New York City. Keith Bryant, Arena's Director, Corporate Development, is scheduled to provide an overview of the company, including its clinical development and discovery programs.
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com/. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. |
| BioTech / BioMedical / Medical |
|
|
| |
| Friday, October 3, 2008 |
 |
|
Essentialis Announces Two Presentations at Upcoming Conferences Posted 6:19 AM PST
|
| |
| Thursday, October 2, 2008 |
|
|
SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis Posted 1:08 PM PST
Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain Posted 10:41 AM PST
|
| |
| Wednesday, October 1, 2008 |
|
|
TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel Posted 6:07 PM PST
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society Posted 6:04 PM PST
University of Southern California Receives Cancer Diagnosis System for Detecting Esophageal Dysplasia Posted 3:52 PM PST
BioMed Realty Trust Announces Public Offering of 7,500,000 Shares of Common Stock Posted 3:51 PM PST
SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification. Posted 3:48 PM PST
Halozyme Therapeutics to Host Research Day for Investors and Analysts Posted 3:46 PM PST
Bio-Matrix Scientific Group, Inc. Receives and Processes First Cord Blood Specimens as Part of the Company’s Quality Assurance Program Posted 7:15 AM PST
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference Posted 4:33 AM PST
|
| |
| Tuesday, September 30, 2008 |
|
|
Genoptix Announces Participation at the Second Annual William Blair Small Cap Growth Conference Posted 10:15 AM PST
Cytori Receives Key Patent for its Cosmetic & Reconstructive Surgery Product Posted 7:54 AM PST
|
| |
| Monday, September 29, 2008 |
|
|
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference Posted 4:46 PM PST
Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting Posted 8:43 AM PST
Bio-Quant Announces the Expansion of Its Research Animal Diagnostic Services to Cover All Nine Species Posted 8:27 AM PST
Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Posted 8:09 AM PST
ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008 Posted 7:44 AM PST
|
| |
| Thursday, September 25, 2008 |
|
|
TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds Posted 9:18 AM PST
CytRx Corporation to Present New Data from Its Proprietary Molecular Chaperone Drug Discovery Technology at the San Diego LEADS Meeting Posted 8:55 AM PST
Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 7:53 AM PST
|
| |
| Wednesday, September 24, 2008 |
|
|
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients Posted 3:09 PM PST
ChemBridge Corporation Enters Into New Discovery Chemistry Strategic Alliance With AstraZeneca Posted 6:40 AM PST
|
| |
| Tuesday, September 23, 2008 |
|
|
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes Posted 4:37 PM PST
Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing Posted 2:54 PM PST
Ebioscience Expands Multicolor Cellular Analysis Portfolio With Introduction of eFluor Brand and Commercial Launch of eFluor Nanocrystal Product Line Posted 8:52 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
